- Open Access
A new parameter using serum lactate dehydrogenase and alanine aminotransferase level is useful for predicting the prognosis of patients at an early stage of acute liver injury: A retrospective study
© Kotoh et al; licensee BioMed Central Ltd. 2008
- Received: 27 December 2007
- Accepted: 14 August 2008
- Published: 14 August 2008
Although most patients with severe acute hepatitis are conservatively cured, some progress to acute liver failure (ALF) with a high rate of mortality. Based on the evidence that over-activation of macrophages, followed by disturbance of the hepatic microcirculation, plays a key role in ALF, we hypothesized that the production of serum lactate dehydrogenase (LDH) might increase in the liver under hypoxic conditions and could be an indicator to discriminate between conservative survivors and fatal patients at an early stage.
To confirm this hypothesis, we developed a new parameter with serum alanine aminotransferase (ALT) and LDH: the ALT-LDH index = serum ALT/(serum LDH - median of normal LDH range). We analyzed retrospectively 33 patients suffering acute liver injury (serum ALT more than 1000 U/L or prothrombin time expressed as international normalized ratio over 1.5 at admission) and evaluated the prognostic value of the ALT-LDH index, comparing data from the first 5 days of hospitalization with the Model for End-Stage Liver Disease (MELD) score. Patients whose symptoms had appeared more than 10 days before admission were excluded from this study. Among those included, 17 were conservative survivors, 9 underwent liver transplantation (LT) and 7 died waiting for LT. We found a rapid increase in the ALT-LDH index in conservative survivors but not in fatal patients. While the prognostic sensitivity and specificity of the ALT-LDH index was low on admission, at day 3 they were superior to the results of MELD.
ALT-LDH index was useful to predict the prognosis of the patients with acute liver injury and should be helpful to begin preparation for LT soon after admission.
- Liver Transplantation
- Hepatic Encephalopathy
- Acute Liver Failure
- Acute Liver Injury
- Hypoxic Hepatitis
Acute liver failure (ALF) or fulminant liver failure is a disease characterized by abrupt onset and high mortality. Liver transplantation (LT) is the only effective treatment for ALF and many patients die before undergoing LT because of rapid progression of the disease [1, 2]. Therefore, a prompt decision regarding LT is required following an early determination of prognosis. Among the various clinical selection criteria proposed for LT, the King's College criteria and the Model for End-Stage Liver Disease (MELD) criteria have been applied widely [3, 4]. However, those criteria include some factors reflecting multiple or systemic organ failure, which means that many patients fulfilling the criteria are already too unwell for transplantation to be contemplated. The poor prognosis of ALF seems to be attributable to the definition of the disease itself. Generally, ALF is defined as an acute liver disease complicated with hepatic encephalopathy and severe coagulopathy. Considerable efforts made in the past to improve the prognosis of ALF have shown limitations. It is well known that supportive methods such as plasma exchange and hemodialysis are not necessarily efficacious once encephalopathy develops in patients suffering from severe acute hepatitis [5–8]. In order to improve the overall prognosis of ALF, it is necessary to seek ways to select patients who have the possibility of developing hepatic encephalopathy before the symptom appears, rather than struggle to cure the patients after fulfilling the ALF criteria. Of course, a new strategy is required to prevent the progression of the disease.
The difficulty in predicting the prognosis of ALF is mainly attributable to incomplete elucidation of its mechanism. The most characteristic pathological finding of ALF is massive necrosis without regeneration, which implies the involvement a disturbance of the hepatic circulation in the progression of the disease. Although this idea is not novel and has not been regarded as important, we believe that it should be revisited, considering recent reports of over-activation of macrophages in the liver, which is believed to cause hepatic hypoxia as a result of disturbance of the microcirculation [9–12]. Although the importance of over-activation of hepatic macrophages in the progression of ALF may be accepted, it is difficult to demonstrate the occurrence of this phenomenon. Whilst liver biopsy is a reliable means of confirming macrophage proliferation in the liver, it carries a risk of bleeding, especially with the coagulopathy seen in ALF. Therefore, we focused on lactate dehydrogenase (LDH), which is recognized as an enzyme released in liver injury, as are aspartate aminotransferase and alanine aminotransferase (ALT). It is common to regard monitoring serum LDH as of little value because it is produced in various organs and the specificity for liver disease is low. However, in ischemic liver disease, the elevation of serum LDH is more pronounced than that of ALT [13–16]. Several pieces of evidence that the production of LDH increases in hypoxic conditions have been reported [17–19]. Another consideration regarding serum LDH in liver disease is its more rapid decline than ALT, because of its shorter half-life in serum . Against the background of these findings, we hypothesized that the ALT-LDH ratio could be a marker indicating the degree of hepatic hypoxia caused by macrophage over-activation, which might be helpful to discriminate between fatal patients and conservative survivors at an early stage of ALF. In this study, we examined retrospectively the correlation between the serum ALT-LDH ratio of the patients suffering from acute liver injury and who had had the possibility of developing ALF and their outcomes, and evaluated the predictive efficacy of this new indicator compared to the MELD scoring system.
Characteristics of the patients.
LT or Death
39.4 ± 15.3
48.3 ± 16.3
43.7 ± 16.2
4122.4 ± 3915.1
3587.3 ± 4123.7
3862.9 ± 3963.4
3845.5 ± 2932.1
2777.8 ± 2850.6
3327.8 ± 2898.5
2668.0 ± 3431.0
2796.1 ± 4093.2
2730.1 ± 3707.3
543.7 ± 168.1
509.4 ± 162.5
527.1 ± 163.7
293.1 ± 200.0
245.8 ± 249.8
270.2 ± 223.2
Total bilirubin (mg/dL)
9.1 ± 6.8
14.6 ± 10.0
11.8 ± 8.8
Direct bilirubin (mg/dL)
6.1 ± 4.7
9.4 ± 6.9
7.6 ± 6.0
3.7 ± 0.4
3.3 ± 0.4
3.5 ± 0.4
2.19 ± 1.56
3.38 ± 2.29
2.76 ± 2.00
Platelet (× 104/μL)
14.9 ± 5.9
11.5 ± 5.9
13.3 ± 6.1
1.14 ± 2.03
1.35 ± 1.61
1.25 ± 1.81
Etiology – HAV
Etiology – HBV
Etiology – Drug
Etiology – Wilson
Etiology – Unknown
17.66 ± 9.79
26.69 ± 11.89
22.0 ± 11.6
ALT-LDH index 3.0
ALT-LDH index ≥ 3.0
ROC curves with MELD score and ALT-LDH index predicting conservative survivors.
Area under ROC
0.582 – 0.918
0.612 – 0.941
0.373 – 0.774
0.770 – 1.02
Prognostic values of MELD score and ALT-LDH index predicting conservative survivors.
MELD (day1) <30
MELD (day1) <35
MELD (day3) <30
MELD (day3) <35
ALT-LDH (day1) >3.0
ALT-LDH (day3) >3.0
In this study we demonstrated the contrasting transitions of the ALT-LDH index in the early stage of acute liver injury between the conservative survivors and the patients with progressive fatal liver failure. In the former, the ALT-LDH index increased abruptly soon after the peak of serum ALT elevation, which was caused by a more rapid decrease of LDH than ALT activity. This phenomenon is convincing because the half-life of serum LDH is normally much shorter than that of serum ALT. On the other hand, in the fatal patients group, a less rapid decrease of serum LDH activity kept the ALT-LDH index low, which implied that the delayed decrease of serum LDH at an early stage of ALF may be closely related to a poor prognosis. This phenomenon might be explained by assuming hypoxic conditions in the livers of the patients with progressive ALF.
Although the mechanism of ALF has not been elucidated fully, several authors recently reported that over-activation of macrophages plays a key role in the progression of ALF [9–12]. The activated and proliferating macrophages in the liver could injure endothelial cells and cause a disturbance in the hepatic microcirculation. We suppose that this may be the main process of ALF, at least for the non-acetaminophen type. Meanwhile, LDH is an essential enzyme involved in anaerobic glycolysis and is responsible for the anaerobic transformation of pyruvate to lactate. Increased expression of LDH under hypoxic conditions has been demonstrated in various cell lines [17–19]. Concerning liver diseases, it is well known that dominant elevation of serum LDH is observed in hypoxic hepatitis caused by shock or heart failure [13–16]. Although the elevation of LDH activity in acute liver injury has been simply supposed to be enzyme leakage through damaged hepatocyte membranes, as the seen with ALT, increased LDH production could also be attributable to anaerobic conditions. The hepatocytes are expected to increase the production of LDH under anaerobic conditions, until they become necrotic. From this viewpoint, the persistent low ALT-LDH index in fatal patients might be the result of increased production of LDH from residual living hepatocytes in hypoxia. Prolonged hypoxic conditions could cause massive or lobular necrosis, which coincides with the pathologic findings of ALF.
When we accept the mechanism described above, acute liver injury could be supposed to consist of two different processes of cell destruction. One is direct cytotoxicity toward hepatocytes caused by various triggers. In most non-acetaminophen hepatitis, cytotoxic T cells attack hepatocytes directly. In this process, the increased release of enzymes into the serum is the result of simple leakage from injured hepatocytes, and enzyme activities decrease rapidly, according to their half-lives, as soon as the triggers are removed or inactivated. The other mechanism is hypoxic liver injury caused by disturbance of the hepatic microcirculation. The persistent low ALT-LDH index may imply the situation that the hypoxic process mainly remains after the removal of the trigger of liver injury. Most acute liver injury might be explained as a mixture of these two mechanisms, to various degrees. The patients shown in Figure 3 are supposed to be representatives of cases that almost lack a hypoxic process.
In the past, many attempts have been made to predict the prognosis of ALF [21–24]. However, it is impossible to estimate the prognosis using data from a single time point at a very early stage because ALF is a disease with rapid progression and patients may present at various phases of the clinical course. The MELD score is certainly useful to predict the prognosis of patients awaiting LT. However, as shown by our results, its sensitivity remained very low over several days after admission. It is a matter of course because the MELD score was determined principally using data from patients in their end stage. On the other hand, while the sensitivity and specificity of the ALT-LDH index were rather poor on admission, both were improved dramatically beyond the MELD score at day 3. That is, the ALT-LDH index could reflect the rapid clinical change of ALF. We emphasize that the important thing is to observe the transition of clinical data, not simply a single time-point, in a disease with rapid progression, such as ALF.
In this study, we showed the efficacy of the ALT-LDH index to predict the prognosis of patients with acute liver injury at their early stages. This index should enable us to begin preparation for LT shortly after admission. We believe that the index could be a support for other indicators, such as the MELD score. However, the number of the enrolled patients into this study was not enough. The further evaluation in larger prospective clinical studies is required.
Patients with severe acute liver injury referred to our hospital for consideration for LT between April 2000 and March 2004 were analyzed retrospectively. Among them, those with serum ALT activity more than 1000 U/L or prothrombin time expressed as international normalized ratio (PT-INR) over 1.5 were enrolled into this study, amounting to 33 patients (Table 1). In order to focus on the early phase of ALF, those in whom the onset of any of clinical symptoms, such as general fatigue, appetite loss, nausea and jaundice, had begun 10 days before admission were excluded from this study. Hepatic encephalopathy grade 2 or more was seen in 11 (33%) on admission. The etiology of liver injury varied: 6 hepatitis A virus (HAV), 13 hepatitis B virus (HBV), 3 drugs other than acetaminophen, 2 Wilson's disease and 9 indeterminate. Laboratory data were checked daily in the morning. Plasma exchange was performed in the afternoon when hepatic encephalopathy was greater than grade 2 or prolonged downhill PT activity was observed. Among the enrolled patients, 17 were conservative survivors, 9 underwent LT and 7 died waiting for LT. In following analysis we considered the fatal patients and those who were transplanted as one category because the pathological examination showed that the livers of all transplant recipients were markedly atrophic and entirely necrotized, which indicated that they would have not been able to survive without LT.
The serum ALT and LDH activities were measured using the 7500 Clinical Analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan). LDH was assayed using an enzymatic rate method with lactate as the substrate (lactate-pyruvate direction). ALT assay was performed without pyridoxal phosphate supplementation. The normal ranges of ALT and LDH were 6–30 U/L and 119–229 U/L, respectively. We aimed to evaluate the increase of these enzymes above normal levels and developed a new index calculated by following formula:
ALT-LDH index = serum ALT/(serum LDH - median of normal LDH range)
In acute liver injury, both serum ALT and LDH commonly decrease after the peak observed in the acute phase regardless of the prognosis. However, in the patients with fatal prognosis, the decrease of serum LDH is expected to delay compared with that of serum ALT, which would be caused by microcirculation disturbance in liver. Therefore, if we use the serum LDH value as a predictive marker of ALF, it should be evaluated under connection with the serum ALT value. Although the simple ALT/LDH ratio seems to be acceptable in evaluation of the serum activity of LDH connecting to ALT, it could not reflect the degree of those enzymes' elevation from normal level when they are in relatively low levels because of the difference of their normal ranges. On the other hand, the value of ALT-LDH index distinctly increases when the serum LDH decreases close to the normal range.
For the enrolled patients, this index was calculated for the first 5 days from their admission, comparing the changes in serum ALT activity during the same period. According to the normal range of our assay system, the median of the serum LDH was calculated as 174 U/L in this study.
Differences in clinical backgrounds and laboratory data between conservative survivors and fatal patients, including those who underwent LT, were analyzed using the Χ2-test and Student t-test. The utilities of the ALT-LDH index and MELD score were evaluated using receiver operating characteristic (ROC) curves. The sensitivity, specificity, positive and negative predictive values (PPV and NPV), efficiency, and area under the ROC curve were calculated for each indicator.
We would like to acknowledge the excellent secretarial assistance of Yuko Kuribayashi for preparing the figures.
- O'Grady JG, Wendon J, Tan KC, Potter D, Cottam S, Cohen AT, Gimson AE, Williams R: Liver transplantation after paracetamol overdose. BMJ. 1991, 303: 221-223.PubMed CentralView ArticlePubMedGoogle Scholar
- Bernal W, Wendon J, Rela M, Heaton N, Williams R: Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology. 1998, 27: 1050-1055. 10.1002/hep.510270421.View ArticlePubMedGoogle Scholar
- O'Grady JG, Alexander GJ, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989, 97: 439-445.PubMedGoogle Scholar
- Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR: A model to predict survival in patients with end-stage liver disease. Hepatology. 2001, 33: 464-470. 10.1053/jhep.2001.22172.View ArticlePubMedGoogle Scholar
- Akdogan M, Camci C, Gurakar A, Gilcher R, Alamian S, Wright H, Nour B, Sebastian A: The effect of total plasma exchange on fulminant hepatic failure. J Clin Apher. 2005, 21: 96-99. 10.1002/jca.20064.View ArticleGoogle Scholar
- Davenport A, Will EJ, Davison AM: Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl. 1993, 41: S245-251.PubMedGoogle Scholar
- Sato S, Suzuki K, Takikawa Y, Endo R, Omata M: Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Hepatol Res. 2004, 30: 155-161. 10.1016/j.hepres.2004.08.003.View ArticlePubMedGoogle Scholar
- Sekido H, Matsuo K, Takeda K, Ueda M, Morioka D, Kubota T, Tanaka K, Endo I, Togo S, Shimada H: Usefulness of artificial liver support for pretransplant patients with fulminant hepatic failure. Transplant Proc. 2004, 36: 2355-2356. 10.1016/j.transproceed.2004.06.040.View ArticlePubMedGoogle Scholar
- Mita A, Hashikura Y, Tagawa Y, Nakayama J, Kawakubo M, Miyagawa S: Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Am J Gastroenterol. 2005, 100: 2551-2559. 10.1111/j.1572-0241.2005.00265.x.View ArticlePubMedGoogle Scholar
- Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K: Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res. 2004, 29: 202-206. 10.1016/j.hepres.2004.03.009.View ArticlePubMedGoogle Scholar
- Iwaki T, Sugimura M, Nishihira J, Matsuura T, Kobayashi T, Kanayama N: Recombinant adenovirus vector bearing antisense macrophage migration inhibitory factor cDNA prevents acute lipopolysaccharide-induced liver failure in mice. Lab Invest. 2003, 83: 561-570.View ArticlePubMedGoogle Scholar
- Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M: Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol. 2005, 40: 52-56. 10.1007/s00535-004-1493-8.View ArticlePubMedGoogle Scholar
- Cassidy WM, Reynolds TB: Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol. 1994, 19: 118-121. 10.1097/00004836-199409000-00008.View ArticlePubMedGoogle Scholar
- Rotenberg Z, Weinberger I, Davidson E, Fuchs J, Harell D, Agmon J: Alterations in total lactate dehydrogenase and its isoenzyme-5 in hepatic disorders. Ann Clin Lab Sci. 1990, 20: 268-273.PubMedGoogle Scholar
- Fuchs S, Bogomolski-Yahalom V, Paltiel O, Ackerman Z: Ischemic hepatitis: clinical and laboratory observations of 34 patients. J Clin Gastroenterol. 1998, 26: 183-186. 10.1097/00004836-199804000-00007.View ArticlePubMedGoogle Scholar
- Henrion J, Colin L, Schapira M, Heller FR: Hypoxic hepatitis caused by severe hypoxemia from obstructive sleep apnea. J Clin Gastroenterol. 1997, 24: 245-249. 10.1097/00004836-199706000-00013.View ArticlePubMedGoogle Scholar
- Koukourakis MI, Pitiakoudis M, Giatromanolaki A, Tsarouha A, Polychronidis A, Sivridis E, Simopoulos C: Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Sci. 2006, 97: 1056-1060. 10.1111/j.1349-7006.2006.00298.x.View ArticlePubMedGoogle Scholar
- Rees BB, Bowman JA, Schulte PM: Structure and sequence conservation of a putative hypoxia response element in the lactate dehydrogenase-B gene of Fundulus. Biol Bull. 2001, 200: 247-251. 10.2307/1543505.View ArticlePubMedGoogle Scholar
- Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ: Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. Proc Natl Acad Sci USA. 1994, 91: 6496-6500. 10.1073/pnas.91.14.6496.PubMed CentralView ArticlePubMedGoogle Scholar
- Itoh N, Yokota H, Yuasa A: Serum enzyme activity evaluated in budgerigars (Melopsittacus undulatus) inflicted with muscle injury. Res Vet Sci. 1993, 55: 275-280.View ArticlePubMedGoogle Scholar
- Blei AT: Selection for acute liver failure: have we got it right?. Liver Transpl. 2005, 11: S30-34. 10.1002/lt.20595.View ArticlePubMedGoogle Scholar
- Neuberger J: Prediction of survival for patients with fulminant hepatic failure. Hepatology. 2005, 41: 19-22. 10.1002/hep.20562.View ArticlePubMedGoogle Scholar
- O'Grady JG: Acute liver failure. Postgrad Med J. 2005, 81: 148-154. 10.1136/pgmj.2004.026005.PubMed CentralView ArticlePubMedGoogle Scholar
- Sass DA, Shakil AO: Fulminant hepatic failure. Liver Transpl. 2005, 11: 594-6. 10.1002/lt.20435.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.